Publications & News | SILLAJEN

Publications & News

Targeting, Attacking, and Eradicating Cancers®

Publications & News

게시판

Total 31. ˙ 1/4 Page

31 How SJ-607’s Antibody-Evasion Technology Could Revolutionize Cancer Treatment 2026-10-13
30 FDA Designates BAL0891 as Rare Drug for Acute Myeloid Leukemia: What This Means for Cancer Treatment in Asia 2026-10-13
29 Revolutionary Cancer Treatment SJ-650: What Makes It a Game Changer in Oncology? 2026-10-13
28 SillaJen: First to use lab-grown human tissue to find best cancer drug dose 2025-03-19
27 [AACR] Sillajen’s TNBC candidate BAL0891 study results accepted for three poster presentations 2025-01-16
26 SillaJen to receive 'PD-1 inhibitor' from BeiGene for 'BAL0891' combination clinical trial 2025-01-16
25 SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC 2024-07-02
24 SillaJen Announces First Patient Enrolled in Part 2 of Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's Libtayo® (cemiplimab-rwlc) 2019-06-10
23 SillaJen and Lee's Pharmaceutical Announce First Patient Enrolled in the PHOCUS Trial in China Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer 2018-09-04
22 SillaJen Announces First Patient Enrolled in Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron’s Cemiplimab 2018-06-20